July 2020 FDA Recall Drug by Taro Pharmaceuticals U.s.a., Inc.
D-1496-2020 - Failed Content Uniformity
This Class III drug recall was voluntarily initiated by Taro Pharmaceuticals U.s.a., Inc. on July 20, 2020 for the product Drug. The FDA reported the reason for recall as failed content uniformity. The product was distributed Nationwide and the recall is currently terminated.
Recall Number: D-1496-2020
Failed Content Uniformity: bulk lot used to make these two lots was found to have failed content uniformity.
07-20-2020
08-19-2020
7632 tubes
Recall Profile & Regulatory Data
Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
Taro Pharmaceuticals U.S.A., Inc.
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
Nationwide in the U.S.
06-20-2023
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Clobetasol Propionate Cream USP, 0.05%, a) 15 g tube, NDC: 60429-902-15; b) 45 g tube, NDC: 60429-902-45, Rx Only, For External Use Only, Not for Ophthalmic Use, Mfd by: Taro Pharmaceuticals Inc. Brampton, Ontario, Canada L6T 1C1, Marketed by: Golden State Medical Supply, Inc. Camarillo, CA 93012.
Batch or Lot Expiration Information
Lot# a) AB28353, Exp 12/31/2021; b) AB40178, Exp 12/31/2021